The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-No auction for Vectura as Carlyle declares $1.3 bln takeover bid final

Tue, 10th Aug 2021 17:02

(Recasts, adds detail, background)

By Yadarisa Shabong

Aug 10 (Reuters) - The takeover battle between tobacco giant
Philip Morris and private equity firm Carlyle for
inhaled treatments maker Vectura will not be heading to
the auction ring on Wednesday after Carlyle said it will not
raise its bid.

U.S.-based Carlyle on Tuesday declared final its 155 pence
per Vectura share offer, which it sweetened last week to value
the British company at about 958 million pounds ($1.33 billion).
The proposal is below an increased 165 pence bid from Philip
Morris on Sunday.

Britain's takeover regulator on Monday had intervened in the
battle, saying that it would enter a rare head-to-head auction https://www.reuters.com/world/uk/britains-takeover-regulator-intervenes-battle-drugmaker-vectura-2021-08-09
if the bidders do not make final bids by Tuesday 1600 GMT (1700
BST).

Only a handful of British takeover fights have gone to
auction, with the highest profile in recent years being the
battle in 2018 for pay-television group Sky when Comcast
emerged as the winner of a single-day three round
blind auction.

London-listed shares of Vectura closed at 163.4 pence on
Tuesday after hitting a more than five-year high of 176 pence
earlier in the session. They have gained 33% in value since
Carlyle's first offer in May.

Vectura has been the target of several approaches since May
from the U.S.-based groups, which are eyeing the drugmaker's
expertise with inhalable formulations and device designs for
respiratory therapies for illnesses such as asthma.

The London-listed company had voiced its support for the
Carlyle offer last week, saying that it may be better positioned
under the ownership of the private equity firm, while noting the
uncertainties that could arise for its stakeholders as a result
of being owned by the Marlboro cigarette-maker.

However, Vectura withdrew its backing and also withheld
support for the higher offer from Philip Morris following the
intervention from the Takeover Panel.

Vectura did not immediately respond to a request for
comment.

A deal with either one of the U.S. companies would require
shareholder approval.
($1 = 0.7229 pounds)

(Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak
Dasgupta and Lisa Shumaker)

More News
26 Nov 2018 09:05

Vectura Discontinues VR375 As Phase Three Study Misses Endpoints

LONDON (Alliance News) - Respiratory disease-focused pharmaceutical firm Vectura Group PLC said on Monday its phase three study of VR375 in adult and adolescent patients with severe uncontrolled a

Read more
22 Oct 2018 08:59

Vectura Says New Chief Financial Officer Fry Has Started Week Early

LONDON (Alliance News) - Medical devices developer Vectura Group PLC said Monday Paul Fry will become chief financial officer immediately, rather than from Monday next week.Fry succeeds who

Read more
11 Sep 2018 09:40

Vectura Interim Loss Narrows On Higher Revenue And Lower Expenses

LONDON (Alliance News) - Pharmaceutical firm Vectura Group PLC on Tuesday said its loss narrowed in the first half of 2018 as it reduced operating costs.Pretax loss narrowed to GBP29.9 in a

Read more
11 Sep 2018 08:18

Vectura's solid interims turn focus further forward

(Sharecast News) - Vectura kept guidance for the full year unchanged as the inhaled medicines specialist reported robust revenue and said it has identified pipeline projects with potential annual sales of over $250m.

Read more
10 Sep 2018 12:49

Vectura Launches Flutiform Inhaler In The UK, Europe To Follow

LONDON (Alliance News) - Vectura Group PLC said Monday that it launched its flutiform k-haler, an inhaler to treat asthma, in the UK.The company said it expects further launches across to a

Read more
4 Sep 2018 15:54

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 5 SeptemberĀ Barratt DevelopmentsFull Year ResultsBreedon GroupHalf Year Year 6

Read more
23 Aug 2018 14:17

Thursday broker round-up

(Sharecast News) - TalkTalk: Barclays upgrades to overweight with a target price of 150p.

Read more
21 Aug 2018 12:31

Vectura concludes two paediatric studies into VR647

(Sharecast News) - Vectura announced the successful conclusion of two paediatric studies to support the potential use of VR647, its wholly-owned drug/device combination asset, on Tuesday.

Read more
21 Aug 2018 09:45

Vectura Group Gets Positive Results From VR647 Phase II Study

LONDON (Alliance News) - Vectura Group PLC said Tuesday that it received positive results form two paediatric studies of its VR647 inhalation system to manage asthma.The two studies, a and

Read more
17 May 2018 10:55

Vectura Group On Track To Achieve Expected Full-Year Revenue

LONDON (Alliance News) - Inhaled product design and development firm Vectura Group PLC said on Thursday based on its trading performance for the year-to-date revenue is currently in line with is a

Read more
11 May 2018 11:35

Nuformix Appoints Former Ventura Chief Executive To Board

LONDON (Alliance News) - Pharmaceutical company Nuformix PLC said Friday that it has appointed Christopher Blackwell, the former chief executive officer of Vectura Group PLC, as non-executive of a

Read more
10 May 2018 16:16

UK Shareholder Meetings Calendar - Next 7 Days

Friday 11 MayBBA AviationMan GroupRSA Insurance GroupJohn Wood Advanced 14 15 Pacific

Read more
24 Apr 2018 13:16

Sosei Group Confirms It Will Not Make Takeover Offer For Vectura

LONDON (Alliance News) - Japanese biotechnology firm Sosei Group Corp said on Tuesday, noting unspecified press reports, it does not intend to make an offer for Vectura Group PLC.Shares in

Read more
23 Apr 2018 09:55

Vectura Adds Ex-GSK And Sanofi Executive Whitaker To Board From June

LONDON (Alliance News) - Vectura PLC said Monday it has appointed Anne Whitaker as non-executive director of the drug development firm from the start of June.Whitaker served as president of

Read more
20 Apr 2018 09:59

Vectura CFO Andrew Derodra Leaves To Take Up Role At Unilabs

LONDON (Alliance News) - Vectura Group PLC on Friday said that its Chief Financial Officer Andrew Derodra will leave the FTSE 250-listed respiratory medicines maker to take a new role within the a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.